Sekisui XenoTech
Sekisui XenoTech, a member of the BioIVT family, specializes in ADME/DMPK/DDI testing and offers a comprehensive range of in vitro and in vivo research services for drug metabolism and drug-drug interaction studies to the global pharmaceutical industry.
Services
Sekisui XenoTech specializes in ADME/DMPK/DDI testing of potential drug candidates. Their suite of services includes enzyme inhibition, enzyme induction, drug transporters, metabolite identification, reaction phenotyping, metabolic stability, predictive screening, plasma protein binding, lysosomal trapping, analytical services (bioanalysis), and biologic-small molecule DDI. They cater to pharmaceutical companies worldwide, providing critical data needed to guide drug development processes and ensure regulatory compliance.
Products
Sekisui XenoTech offers various test systems essential for drug testing and research. These include human hepatocytes, animal hepatocytes, Kupffer cells, subcellular fractions, tissue & arrays, JCRB cell bank, recombinant enzymes, and P450 substrates & metabolites. These products support both in vitro and in vivo studies, helping pharmaceutical companies perform rigorous testing of drug candidates and understand drug metabolism and interactions.
In Vivo Research Capabilities
Sekisui XenoTech provides comprehensive in vivo research services. These include tissue distribution, metabolite identification, excretion/mass balance, pharmacokinetics/rat PK, plasma protein binding, and radioreceptor assays. These services enhance the understanding of drug disposition within a living organism, providing vital data for drug development and regulatory submissions.
Consulting Services
Sekisui XenoTech offers expert consulting services to pharmaceutical companies. This includes gap analyses for in vitro DDI and drug metabolism, planning risk-based approaches, strategic timing advice, responses to regulatory questions, design of introductory in vitro DDI study packages, mechanistic static modeling for DDIs, basic in vitro-in vivo extrapolation (IVIVE) scaling for clearance (CLint), synthesis of in vitro DDI data, and expert commentary on DDI and metabolism data. These services help clients navigate the complexities of drug development and regulatory processes.
Sector
Sekisui XenoTech operates within the pharmaceutical research sector, focusing specifically on drug metabolism and drug-drug interaction studies. As part of the BioIVT family, the company leverages extensive expertise and resources to offer specialized testing and consulting services. Their work supports the pharmaceutical industry by enhancing the safety and efficacy profiles of new drug candidates.